In Part 1, after regulation 2 (interpretation and introduction of Schedules 1 to 4) insert—
Exemptions for vaccinated travellers and others
(2A)
(1) In these Regulations, a person (“P”) is an eligible category 2 arrival if P meets the requirements of paragraph (2) and any of paragraphs (3) to (6) of this regulation.
(2) In the period beginning with the 10th day before the date of P’s arrival in England—
(a) P has been in a category 2 country or territory other than Metropolitan France; and
(b) P has not been in Metropolitan France or a category 3 country or territory.
(3) P—
(a) has completed a course of doses of an authorised vaccine with the final dose having been received before the start of the period beginning with the 14th day before the date of their arrival in England;
(b) received that course of doses in the United Kingdom;
(c) is able to provide proof if required by an immigration officer or the operator of the relevant service on which P travels to England of meeting the requirement in sub-paragraph (a) through the NHS COVID pass, or equivalent from NHS Scotland, NHS Wales or the Department of Health in Northern Ireland; and
(d) has declared on the Passenger Locator Form that P meets the COVID-19 vaccination eligibility criteria for reduced isolation and testing requirements.
(4) P—
(a) has participated, or is participating, in a clinical trial of a vaccine for vaccination against coronavirus carried out in accordance with the requirements of the Medicines for Human Use (Clinical Trials) Regulations 2004 ;
(b) is able to provide proof of such participation; and
(c) has declared on the Passenger Locator Form that P meets the COVID-19 vaccination eligibility criteria for reduced isolation and testing requirements.
(5) P is—
(a) under the age of 18 years upon arrival in England; and
(b) ordinarily resident in the United Kingdom.
(6) P is either—
(a) a person who—
(i) has completed a course of doses of a vaccine under the United Kingdom vaccine roll-out overseas, with the final dose having been received before the start of the period beginning with the 14th day before the date of their arrival in England,
(ii) is able to provide proof if required by an immigration officer or the operator of the relevant service on which P travels to England of meeting the requirements in paragraph (i), and
(iii) has declared on the Passenger Locator Form that P meets the COVID-19 vaccination eligibility criteria for reduced isolation and testing requirements; or
(b) a dependant of a person of the description in any of paragraphs (a) to (c) of the definition of “United Kingdom vaccine roll-out overseas” and is under the age of 18 years upon arrival in England.
(7) For the purposes of paragraphs (3) and (6), P has completed a course of doses if P has received the complete course of doses specified—
(a) in the summary of product characteristics approved as part of the marketing authorisation for the authorised vaccine; or
(b) in the instructions for usage approved as part of the authorisation by the licensing authority on a temporary basis under regulation 174 (supply in response to spread of pathogenic agents etc) of the Human Medicines Regulations 2012 for the authorised vaccine.
(8) For the purposes of paragraph (6), where P has received a dose of an authorised vaccine in the United Kingdom and a dose of a vaccine under the United Kingdom vaccine roll-out overseas, P is deemed to have received a course of doses of a vaccine under the United Kingdom vaccine roll-out overseas.
(9) For the purposes of this regulation—
(a) a child is to be treated as making a declaration on a Passenger Locator Form, and providing any proof required, if that declaration is made, and the proof provided, by a person who is travelling with and has responsibility for that child;
(b) a person is not treated as having been in a country or territory if that person would not be treated as having departed from or transited through that country or territory by virtue of regulation 2(3).
(10) In this regulation—
“authorised vaccine” means a medicinal product for vaccination against coronavirus—
authorised for supply in the United Kingdom in accordance with a marketing authorisation, or
authorised by the licensing authority on a temporary basis under regulation 174 of the Human Medicines Regulations 2012;
“clinical trial” has the meaning given in regulation 2(1) of the Medicines for Human Use (Clinical Trials) Regulations 2004;
“Crown servant” has the meaning given in section 12(1)(a) to (e) of the Official Secrets Act 1989 ;
“government contractor” has the meaning given in section 12(2) of the Official Secrets Act 1989;
“the licensing authority” has the meaning given in regulation 6(2) (the licensing authority and the Ministers) of the Human Medicines Regulations 2012;
“marketing authorisation” has the meaning given in regulation 8(1) (general interpretation) of the Human Medicines Regulations 2012;
“medicinal product” has the meaning given in regulation 2 (medicinal products) of the Human Medicines Regulations 2012;
“NHS COVID pass” means the COVID-19 records on the NHS smartphone app developed and operated by the Secretary of State, through the website at NHS.uk or a COVID-19 post vaccination letter obtained from the NHS;
“NHS” means the health service continued under section 1(1) of the National Health Service Act 2006 ;
“NHS Scotland” means the health service continued under section 1(1) of the National Health Service (Scotland) Act 1978 ;
“NHS Wales” means the health service continued under section 1(1) of the National Health Service (Wales) Act 2006 ;
“United Kingdom vaccine roll-out overseas” means the administration of vaccination against coronavirus to—
Crown servants, government contractors or other personnel posted or based overseas and their dependants under the scheme known as the Foreign, Commonwealth and Development Office staff COVID-19 vaccination programme;
residents of the British overseas territories, the Channel Islands and the Isle of Man, as part of a programme agreed in the overseas territory, any of the Channel Islands, or the Isle of Man with the United Kingdom government; or
military or civilian personnel, government contractors and their dependants at a military posting overseas, including the British overseas territories, the Channel Islands and the Isle of Man, under the vaccination scheme provided or approved by the UK Defence Medical Services.